Insight into Otezla
Otezla (apremilast) was approved in the United States on March 21, 2014, for the treatment of psoriatic arthritis. It was approved in the United States on September 23, 2014, for the treatment of psoriasis. Otezla adds strength to Celgene’s (CELG) Inflammation and Immunology segment.
Otezla has been witnessing good growth. In 3Q15, revenues generated from Otezla stood at $139 million. US domestic market sales were $129 million. International market sales were $10 million.
The above graph reflects revenues of Otezla in the United States and in international markets since 4Q14.
Otezla is gaining market share. It’s poised to give good competition to AbbVie’s (ABBV) Humira and Johnson & Johnson’s (JNJ) Stelara and Enbrel, which is jointly marketed by Amgen (AMGN) and Pfizer (PFE). Analysts are expecting ~$169 million in revenue for 4Q15 from Otezla. They expect revenue to grow, as it will be launched in Canada, Germany, and other European countries.
Celgene has a strong pipeline, and clinical trials activity can be seen across its portfolio. Below is an updated status of Celgene’s key clinical trials:
- Phase 3 trial of Ozanimod in moderate-to-severe ulcerative colitis and relapsing multiple sclerosis is in progress. The clinical trial data are expected at the beginning of 2017.
- Celgene has completed the enrollment for the Phase 3 trial of Otezla in active Behçet’s disease.
- Celgene has completed the enrollment for the Phase 2 trial of Otezla in ulcerative colitis.
- Celgene has completed the enrollment for the clinical trial of Ozanimod in Crohn’s disease.
On December 6, 2015, at the 57th American Society of Hematology Annual Meeting, Celgene announced nearly 30 combination studies. They include immunomodulatory drugs, Revlimid, and Pomalyst for patients with multiple myeloma.
The Power Shares QQQ ETF (QQQ) holds 1.6% of its portfolio in Celgene.